Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.70 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22619593 | 0.82 | TRPC5 (1.00) | SMN1; SMN2HTTMAPK1USP2TRPC5 | |
| SCHEMBL29646286 | 0.82 | TRPC5 (1.00) | SMN1; SMN2HTTMAPK1USP2TRPC5 | |
| SCHEMBL20715695 | 0.78 | SMN1; SMN2 (0.76) | SMN1; SMN2HTTMEN1KMT2AMAPK1 | |
| SCHEMBL20715322 | 0.76 | SMN1; SMN2 (0.81) | SMN1; SMN2HTTMEN1KMT2AMAPK1 | |
| SCHEMBL3022079 | 0.76 | MAPT (0.86) | SMN1; SMN2HTTMEN1KMT2AMAPK1 | |
| SCHEMBL20715446 | 0.74 | TP53 (1.00) | SMN1; SMN2HTTMEN1KMT2AMAPK1 | |
| SCHEMBL19714457 | 0.74 | TSHR (0.71) | SMN1; SMN2HTTMEN1KMT2AMAPK1 | |
| SCHEMBL27898285 | 0.74 | ALDH1A1 (0.83) | SMN1; SMN2HTTMEN1KMT2AMAPK1 | |
| SCHEMBL20715316 | 0.71 | USP2 (0.83) | SMN1; SMN2HTTMEN1KMT2AMAPK1 | |
| SCHEMBL3022255 | 0.71 | MAPT (1.00) | SMN1; SMN2HTTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-12-03 | — | — | US | disclosed |
| WO-2019028308-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | AZI2, ATP6V1B1, GLS | SMN1; SMN2 3564/4885HTT 3957/4885MEN1 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.